Symbols / TELO $1.27 -3.79% Telomir Pharmaceuticals, Inc.
TELO Chart
About
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 43.66M |
| Enterprise Value | 36.85M | Income | -10.41M | Sales | — |
| Book/sh | 0.17 | Cash/sh | 0.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.54 | PEG | — |
| P/S | — | P/B | 7.38 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 5.10 |
| Current Ratio | 5.14 | Debt/Eq | 8.01 | LT Debt/Eq | — |
| EPS (ttm) | -0.33 | EPS next Y | -0.28 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 16:00 | ROA | -152.03% |
| ROE | -3.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 34.38M |
| Shs Float | 19.03M | Short Float | 6.15% | Short Ratio | 15.09 |
| Short Interest | — | 52W High | 3.23 | 52W Low | 1.05 |
| Beta | -0.73 | Avg Volume | 110.41K | Volume | 87.42K |
| Target Price | — | Recom | None | Prev Close | $1.32 |
| Price | $1.27 | Change | -3.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.27
Latest analyst target
3. DCF / Fair value
$-0.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.27
Low
—
High
—
Mean
—
- Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan ue, 31 Mar 2026 12
- Telo Genomics Corp (3D0A.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada hu, 02 Apr 2026 06
- Telomir Sets Vote on Transformative TELI Merger and Governance Changes - TipRanks hu, 19 Feb 2026 23
- TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - Stocktwits Fri, 21 Nov 2025 08
- Telomir stock soars after tumor suppressor gene reactivation results - Investing.com ue, 07 Oct 2025 07
- Telomir’s Nasdaq Compliance Removes Listing Risk—But Survival Now Hinges on $5M Funding Milestones - Bitget ue, 31 Mar 2026 06
- Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - Stock Titan ue, 31 Mar 2026 13
- Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks ue, 31 Mar 2026 21
- Rodman & Renshaw initiates Telomir Pharma stock with Buy rating - Investing.com ue, 13 Jan 2026 08
- Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today - Stocktwits hu, 09 Oct 2025 07
- Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - Stock Titan ue, 31 Mar 2026 11
- Telomir Pharmaceuticals shareholders approve acquisition and bylaw changes - Investing.com Fri, 27 Mar 2026 07
- Telomir Shareholders Approve Equity Plan and Bylaw Changes - TipRanks Sat, 28 Mar 2026 02
- Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - Stock Titan Fri, 27 Mar 2026 21
- New CEO takes over at Telo Genomics as founder stays a director - Stock Titan ue, 31 Mar 2026 11
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
10.54
-13.91%
|
12.24
+210.55%
|
3.94
+361.52%
|
0.85
|
| Research And Development |
|
2.44
+8.96%
|
2.24
+41.99%
|
1.57
+88.95%
|
0.83
|
| Selling General And Administration |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| General And Administrative Expense |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| Other Gand A |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| Other Operating Expenses |
|
—
|
0.37
-79.04%
|
1.77
|
—
|
| Total Expenses |
|
10.54
-13.91%
|
12.24
+210.55%
|
3.94
+361.52%
|
0.85
|
| Operating Income |
|
-10.54
+13.91%
|
-12.24
-210.55%
|
-3.94
-361.52%
|
-0.85
|
| EBITDA |
|
-10.41
+14.61%
|
-12.19
-6.70%
|
-11.43
-1238.04%
|
-0.85
|
| Normalized EBITDA |
|
-10.41
+14.61%
|
-12.19
-209.34%
|
-3.94
-361.52%
|
-0.85
|
| EBIT |
|
-10.41
+14.61%
|
-12.19
-6.70%
|
-11.43
-1238.04%
|
-0.85
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Other Special Charges |
|
—
|
—
|
7.49
|
—
|
| Net Income |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Pretax Income |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Non Operating Interest Income Expense |
|
0.13
+102.93%
|
-4.29
-161.13%
|
-1.64
|
0.00
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
4.34
+164.05%
|
1.64
|
0.00
|
| Net Interest Income |
|
0.13
+102.93%
|
-4.29
-161.13%
|
-1.64
|
0.00
|
| Interest Expense |
|
0.00
-100.00%
|
4.34
+164.05%
|
1.64
|
0.00
|
| Interest Income Non Operating |
|
0.13
+161.76%
|
0.05
|
0.00
|
—
|
| Interest Income |
|
0.13
+161.76%
|
0.05
|
0.00
|
—
|
| Other Income Expense |
|
—
|
—
|
-7.49
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income From Continuing And Discontinued Operation |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income Continuous Operations |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Normalized Income |
|
-10.41
+37.01%
|
-16.53
-196.01%
|
-5.59
-553.88%
|
-0.85
|
| Net Income Common Stockholders |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Diluted EPS |
|
—
|
-0.56
-26.85%
|
-0.44
-1430.39%
|
-0.03
|
| Basic EPS |
|
—
|
-0.56
-26.85%
|
-0.44
-1430.39%
|
-0.03
|
| Basic Average Shares |
|
—
|
29.54
-0.24%
|
29.61
+0.00%
|
29.61
|
| Diluted Average Shares |
|
—
|
29.54
-0.24%
|
29.61
+0.00%
|
29.61
|
| Diluted NI Availto Com Stockholders |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.34
+454.48%
|
1.32
-72.26%
|
4.77
+9696.36%
|
0.05
|
| Current Assets |
|
7.34
+454.48%
|
1.32
+204.21%
|
0.44
+793.14%
|
0.05
|
| Cash Cash Equivalents And Short Term Investments |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Cash And Cash Equivalents |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Cash Financial |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Prepaid Assets |
|
0.05
-5.50%
|
0.06
+8016.97%
|
0.00
|
0.00
|
| Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.30
+541.04%
|
0.05
|
| Total Non Current Assets |
|
0.00
|
0.00
-100.00%
|
4.34
|
0.00
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
4.34
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.43
+109.70%
|
0.68
-49.01%
|
1.34
+35.45%
|
0.99
|
| Current Liabilities |
|
1.43
+109.70%
|
0.68
-49.01%
|
1.34
+35.45%
|
0.99
|
| Payables And Accrued Expenses |
|
1.43
+109.70%
|
0.68
-44.84%
|
1.23
+25.21%
|
0.99
|
| Payables |
|
1.01
+48.39%
|
0.68
-44.84%
|
1.23
+25.21%
|
0.99
|
| Accounts Payable |
|
0.54
-8.64%
|
0.59
-16.92%
|
0.71
+74.95%
|
0.40
|
| Current Accrued Expenses |
|
0.42
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.10
|
—
|
| Current Debt |
|
—
|
—
|
0.10
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Common Stock Equity |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
34.38
+15.52%
|
29.76
+0.52%
|
29.61
+0.00%
|
29.61
|
| Ordinary Shares Number |
|
34.38
+15.52%
|
29.76
+0.52%
|
29.61
+0.00%
|
29.61
|
| Additional Paid In Capital |
|
46.92
+50.20%
|
31.24
+78.49%
|
17.50
+31722.45%
|
0.06
|
| Retained Earnings |
|
-41.01
-34.03%
|
-30.60
-117.55%
|
-14.06
-1317.36%
|
-0.99
|
| Total Equity Gross Minority Interest |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Total Capitalization |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Working Capital |
|
5.91
+819.60%
|
0.64
+171.42%
|
-0.90
+3.94%
|
-0.94
|
| Invested Capital |
|
5.91
+819.60%
|
0.64
-81.83%
|
3.54
+477.60%
|
-0.94
|
| Total Debt |
|
—
|
—
|
0.10
|
—
|
| Net Debt |
|
—
|
—
|
0.10
|
—
|
| Net Tangible Assets |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Tangible Book Value |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Duefrom Related Parties Current |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Dueto Related Parties Current |
|
0.47
+407.06%
|
0.09
-82.28%
|
0.53
-9.35%
|
0.58
|
| Line Of Credit |
|
—
|
0.00
-100.00%
|
0.10
|
0.00
|
| Other Equity Interest |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Cash Flow From Continuing Operating Activities |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Net Income From Continuing Operations |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Other Non Cash Items |
|
—
|
4.47
+177.30%
|
1.61
|
—
|
| Stock Based Compensation |
|
6.13
-10.73%
|
6.87
|
0.00
|
—
|
| Operating Gains Losses |
|
—
|
—
|
7.49
|
—
|
| Change In Working Capital |
|
0.59
+370.22%
|
0.13
+11.09%
|
0.11
-70.47%
|
0.39
|
| Change In Prepaid Assets |
|
0.00
+105.57%
|
-0.06
-7916.83%
|
-0.00
|
0.00
|
| Change In Payables And Accrued Expense |
|
0.37
+99.70%
|
0.18
+60.30%
|
0.11
-70.28%
|
0.39
|
| Change In Other Working Capital |
|
0.22
|
—
|
—
|
—
|
| Financing Cash Flow |
|
9.71
+53.25%
|
6.34
+64.14%
|
3.86
+721.05%
|
0.47
|
| Cash Flow From Continuing Financing Activities |
|
9.71
+53.25%
|
6.34
+64.14%
|
3.86
+721.05%
|
0.47
|
| Net Issuance Payments Of Debt |
|
0.16
+253.98%
|
-0.10
-106.95%
|
1.45
+214.11%
|
0.46
|
| Issuance Of Debt |
|
0.16
|
0.00
-100.00%
|
1.45
+214.11%
|
0.46
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.10
|
0.00
|
—
|
| Short Term Debt Issuance |
|
0.16
|
0.00
-100.00%
|
1.45
+214.11%
|
0.46
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.10
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.16
+253.98%
|
-0.10
-106.95%
|
1.45
+214.11%
|
0.46
|
| Net Common Stock Issuance |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.04
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
-0.43
-130.84%
|
1.41
+18201.39%
|
0.01
|
| Changes In Cash |
|
6.02
+375.97%
|
1.26
+672919.15%
|
-0.00
-113.25%
|
0.00
|
| Beginning Cash Position |
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
0.00
|
| End Cash Position |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Free Cash Flow |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Common Stock Issuance |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
| Issuance Of Capital Stock |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-27 View
- 10-K2026-03-17 View
- 8-K2026-02-17 View
- 8-K2026-02-05 View
- 8-K2026-01-12 View
- 8-K2026-01-05 View
- 8-K2025-12-22 View
- 8-K2025-12-17 View
- 8-K2025-11-24 View
- 8-K2025-11-20 View
- 8-K2025-11-20 View
- 8-K2025-11-12 View
- 10-Q2025-11-10 View
- 8-K2025-10-22 View
- 8-K2025-10-20 View
- 8-K2025-10-14 View
- 8-K2025-10-08 View
- 8-K2025-10-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|